While intravenous tissue plasminogen activator (IV tPA) remains the mainstay of acute ischemic stroke (AIS) treatment and its use continues to rise1, overall functional outcomes of AIS patients have not improved even with more successful recanalization2, where up to three-quarters of patients experience unfavorable outcomes3. The gene discussed is PLAT; the disease is androgen insensitivity syndrome.